1. Scrip
  2. >>Archive

The Eyes Still Have It: Finding Cures For Diseases that Blind Remains Top Focus for Investors, Entrepreneurs

 
• By Tom Salemi

Over the past few years's there's been no shortage of venture capital investments in companies developing potential treatments for diseases of the eye. Still, investors continue to find entrepreneurs with innovative new approaches to treat age-related macular degeneration, glaucoma and other vision-imparing diseases.

One of the hottest trends in health care investing is as obvious as the eyes on your face. Eye diseases, some of the more disabling maladies affecting aging baby boomers today, continue to draw the attention of venture capitalists and entrepreneurs, including those who have already had success in the field.

But the far-ranging interest in finding cures for crippling diseases like age-related macular degeneration (AMD) and glaucoma (as well as more seemingly benign conditions like conjunctivitis) has been impressive

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.